Shivalik Rasayan Limited
SHIVALIK.NS
₹322.19
▲ 5.00%
Shivalik Rasayan hit its 5% upper circuit to close at ₹322.19 after the company received a Certificate of Suitability for Pirfenidone from the European Directorate for Quality of Medicine & Healthcare, its second regulatory win this year following an earlier China API nod for the anti-leukemia drug Bendamustine that had also triggered a similar rally. The move comes off depressed levels — the stock had been down anywhere between 24% and 59% over the past year and was trading near multi-month lows heading into this news. Valuation-wise, the small-cap pharma name trades at a P/E of 33.74x, a steep 47% discount to its peer group's median of 63.66x, though its longer-term CAGRs across 1, 2, 5 and 10 years are all in negative territory, reflecting how sharp the prior drawdown has been.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| -29.24% | -23.90% | -20.53% | -20.53% |
Related News
No comments:
Post a Comment